TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers

B. Györffy, Giulia Bottai, Jacqueline Lehmann-Che, G. Kéri, L. Őrfi, Takayuki Iwamoto, Christine Desmedt, Giampaolo Bianchini, Nicholas C. Turner, Hugues de Thè, Fabrice André, Christos Sotiriou, Gabriel N. Hortobagyi, Angelo Di Leo, Lajos Pusztai, Libero Santarpia

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Breast cancers (BC) carry a complex set of gene mutations that can influence their gene expression and clinical behavior. We aimed to identify genes driven by the TP53 mutation status and assess their clinical relevance in estrogen receptor (ER)-positive and ER-negative BC, and their potential as targets for patients with TP53 mutated tumors. Separate ROC analyses of each gene expression according to TP53 mutation status were performed. The prognostic value of genes with the highest AUC were assessed in a large dataset of untreated, and neoadjuvant chemotherapy treated patients. The mitotic checkpoint gene MPS1 was the most significant gene correlated with TP53 status, and the most significant prognostic marker in all ER-positive BC datasets. MPS1 retained its prognostic value independently from the type of treatment administered. The biological functions of MPS1 were investigated in different BC cell lines. We also assessed the effects of a potent small molecule inhibitor of MPS1, SP600125, alone and in combination with chemotherapy. Consistent with the gene expression profiling and siRNA assays, the inhibition of MPS1 by SP600125 led to a reduction in cell viability and a significant increase in cell death, selectively in TP53-mutated BC cells. Furthermore, the chemical inhibition of MPS1 sensitized BC cells to conventional chemotherapy, particularly taxanes. Our results collectively demonstrate that TP53-correlated kinase MPS1, is a potential therapeutic target in BC patients with TP53 mutated tumors, and that SP600125 warrant further development in future clinical trials.

Original languageEnglish
Pages (from-to)508-519
Number of pages12
JournalMolecular Oncology
Volume8
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Phosphotransferases
Breast Neoplasms
Recurrence
Mutation
Genes
Neoplasms
Estrogen Receptors
Therapeutics
M Phase Cell Cycle Checkpoints
Gene Expression
Drug Therapy
Taxoids
p53 Genes
Gene Expression Profiling
Combination Drug Therapy
ROC Curve
Small Interfering RNA
Area Under Curve
Cell Survival
Cell Death

Keywords

  • Breast cancer subtypes
  • Chemotherapy
  • MPS1 protein kinase
  • SP600125
  • TP53 mutation status
  • Tumor relapse

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Medicine
  • Medicine(all)

Cite this

TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers. / Györffy, B.; Bottai, Giulia; Lehmann-Che, Jacqueline; Kéri, G.; Őrfi, L.; Iwamoto, Takayuki; Desmedt, Christine; Bianchini, Giampaolo; Turner, Nicholas C.; de Thè, Hugues; André, Fabrice; Sotiriou, Christos; Hortobagyi, Gabriel N.; Di Leo, Angelo; Pusztai, Lajos; Santarpia, Libero.

In: Molecular Oncology, Vol. 8, No. 3, 2014, p. 508-519.

Research output: Contribution to journalArticle

Györffy, B, Bottai, G, Lehmann-Che, J, Kéri, G, Őrfi, L, Iwamoto, T, Desmedt, C, Bianchini, G, Turner, NC, de Thè, H, André, F, Sotiriou, C, Hortobagyi, GN, Di Leo, A, Pusztai, L & Santarpia, L 2014, 'TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers', Molecular Oncology, vol. 8, no. 3, pp. 508-519. https://doi.org/10.1016/j.molonc.2013.12.018
Györffy, B. ; Bottai, Giulia ; Lehmann-Che, Jacqueline ; Kéri, G. ; Őrfi, L. ; Iwamoto, Takayuki ; Desmedt, Christine ; Bianchini, Giampaolo ; Turner, Nicholas C. ; de Thè, Hugues ; André, Fabrice ; Sotiriou, Christos ; Hortobagyi, Gabriel N. ; Di Leo, Angelo ; Pusztai, Lajos ; Santarpia, Libero. / TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers. In: Molecular Oncology. 2014 ; Vol. 8, No. 3. pp. 508-519.
@article{13f72997177846bb94ad15f19271d6f1,
title = "TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers",
abstract = "Breast cancers (BC) carry a complex set of gene mutations that can influence their gene expression and clinical behavior. We aimed to identify genes driven by the TP53 mutation status and assess their clinical relevance in estrogen receptor (ER)-positive and ER-negative BC, and their potential as targets for patients with TP53 mutated tumors. Separate ROC analyses of each gene expression according to TP53 mutation status were performed. The prognostic value of genes with the highest AUC were assessed in a large dataset of untreated, and neoadjuvant chemotherapy treated patients. The mitotic checkpoint gene MPS1 was the most significant gene correlated with TP53 status, and the most significant prognostic marker in all ER-positive BC datasets. MPS1 retained its prognostic value independently from the type of treatment administered. The biological functions of MPS1 were investigated in different BC cell lines. We also assessed the effects of a potent small molecule inhibitor of MPS1, SP600125, alone and in combination with chemotherapy. Consistent with the gene expression profiling and siRNA assays, the inhibition of MPS1 by SP600125 led to a reduction in cell viability and a significant increase in cell death, selectively in TP53-mutated BC cells. Furthermore, the chemical inhibition of MPS1 sensitized BC cells to conventional chemotherapy, particularly taxanes. Our results collectively demonstrate that TP53-correlated kinase MPS1, is a potential therapeutic target in BC patients with TP53 mutated tumors, and that SP600125 warrant further development in future clinical trials.",
keywords = "Breast cancer subtypes, Chemotherapy, MPS1 protein kinase, SP600125, TP53 mutation status, Tumor relapse",
author = "B. Gy{\"o}rffy and Giulia Bottai and Jacqueline Lehmann-Che and G. K{\'e}ri and L. Őrfi and Takayuki Iwamoto and Christine Desmedt and Giampaolo Bianchini and Turner, {Nicholas C.} and {de Th{\`e}}, Hugues and Fabrice Andr{\'e} and Christos Sotiriou and Hortobagyi, {Gabriel N.} and {Di Leo}, Angelo and Lajos Pusztai and Libero Santarpia",
year = "2014",
doi = "10.1016/j.molonc.2013.12.018",
language = "English",
volume = "8",
pages = "508--519",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers

AU - Györffy, B.

AU - Bottai, Giulia

AU - Lehmann-Che, Jacqueline

AU - Kéri, G.

AU - Őrfi, L.

AU - Iwamoto, Takayuki

AU - Desmedt, Christine

AU - Bianchini, Giampaolo

AU - Turner, Nicholas C.

AU - de Thè, Hugues

AU - André, Fabrice

AU - Sotiriou, Christos

AU - Hortobagyi, Gabriel N.

AU - Di Leo, Angelo

AU - Pusztai, Lajos

AU - Santarpia, Libero

PY - 2014

Y1 - 2014

N2 - Breast cancers (BC) carry a complex set of gene mutations that can influence their gene expression and clinical behavior. We aimed to identify genes driven by the TP53 mutation status and assess their clinical relevance in estrogen receptor (ER)-positive and ER-negative BC, and their potential as targets for patients with TP53 mutated tumors. Separate ROC analyses of each gene expression according to TP53 mutation status were performed. The prognostic value of genes with the highest AUC were assessed in a large dataset of untreated, and neoadjuvant chemotherapy treated patients. The mitotic checkpoint gene MPS1 was the most significant gene correlated with TP53 status, and the most significant prognostic marker in all ER-positive BC datasets. MPS1 retained its prognostic value independently from the type of treatment administered. The biological functions of MPS1 were investigated in different BC cell lines. We also assessed the effects of a potent small molecule inhibitor of MPS1, SP600125, alone and in combination with chemotherapy. Consistent with the gene expression profiling and siRNA assays, the inhibition of MPS1 by SP600125 led to a reduction in cell viability and a significant increase in cell death, selectively in TP53-mutated BC cells. Furthermore, the chemical inhibition of MPS1 sensitized BC cells to conventional chemotherapy, particularly taxanes. Our results collectively demonstrate that TP53-correlated kinase MPS1, is a potential therapeutic target in BC patients with TP53 mutated tumors, and that SP600125 warrant further development in future clinical trials.

AB - Breast cancers (BC) carry a complex set of gene mutations that can influence their gene expression and clinical behavior. We aimed to identify genes driven by the TP53 mutation status and assess their clinical relevance in estrogen receptor (ER)-positive and ER-negative BC, and their potential as targets for patients with TP53 mutated tumors. Separate ROC analyses of each gene expression according to TP53 mutation status were performed. The prognostic value of genes with the highest AUC were assessed in a large dataset of untreated, and neoadjuvant chemotherapy treated patients. The mitotic checkpoint gene MPS1 was the most significant gene correlated with TP53 status, and the most significant prognostic marker in all ER-positive BC datasets. MPS1 retained its prognostic value independently from the type of treatment administered. The biological functions of MPS1 were investigated in different BC cell lines. We also assessed the effects of a potent small molecule inhibitor of MPS1, SP600125, alone and in combination with chemotherapy. Consistent with the gene expression profiling and siRNA assays, the inhibition of MPS1 by SP600125 led to a reduction in cell viability and a significant increase in cell death, selectively in TP53-mutated BC cells. Furthermore, the chemical inhibition of MPS1 sensitized BC cells to conventional chemotherapy, particularly taxanes. Our results collectively demonstrate that TP53-correlated kinase MPS1, is a potential therapeutic target in BC patients with TP53 mutated tumors, and that SP600125 warrant further development in future clinical trials.

KW - Breast cancer subtypes

KW - Chemotherapy

KW - MPS1 protein kinase

KW - SP600125

KW - TP53 mutation status

KW - Tumor relapse

UR - http://www.scopus.com/inward/record.url?scp=84899488362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899488362&partnerID=8YFLogxK

U2 - 10.1016/j.molonc.2013.12.018

DO - 10.1016/j.molonc.2013.12.018

M3 - Article

VL - 8

SP - 508

EP - 519

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 3

ER -